Skip to main content
Open Access Publications from the University of California

PCSK9 inhibition to lower LDL-cholesterol and reduce cardiovascular risk: Great expectations

  • Author(s): Waters, DD
  • Hsue, PY
  • et al.

© 2015 American Heart Association, Inc. New clinical trials with the proprotein convertase subtilisin- kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab show that these drugs not only lower lowdensity lipoprotein cholesterol (LDL-C) profoundly, but also seem to reduce cardiovascular events, although the number of events and duration of follow-up are limited. Larger trials are underway to confirm these findings and to document safety.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View